机构:[1]Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.[2]Southern Theater General Hospital of the Chinese People's Liberation Army, Guangzhou, Guangdong, 510010, People's Republic of China.
Science and Technology Innovation Team Project of Hunan Province
(2020RC4050), Hunan Province Traditional Chinese Medicine Research Program Project (E2022010) and Hunan
Province Graduate Research Innovation Project (QL20210175).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|3 区医学
小类|3 区免疫学
最新[2025]版:
大类|3 区医学
小类|3 区免疫学
第一作者:
第一作者机构:[1]Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
通讯作者:
推荐引用方式(GB/T 7714):
Liu Xun,Liu Hua,Deng Yihui.Efferocytosis: An Emerging Therapeutic Strategy for Type 2 Diabetes Mellitus and Diabetes Complications[J].Journal of inflammation research.2023,16:2801-2815.doi:10.2147/JIR.S418334.
APA:
Liu Xun,Liu Hua&Deng Yihui.(2023).Efferocytosis: An Emerging Therapeutic Strategy for Type 2 Diabetes Mellitus and Diabetes Complications.Journal of inflammation research,16,
MLA:
Liu Xun,et al."Efferocytosis: An Emerging Therapeutic Strategy for Type 2 Diabetes Mellitus and Diabetes Complications".Journal of inflammation research 16.(2023):2801-2815